Irak3 Antibody

What is IRAK3 and what is its significance in immune signaling?

IRAK3 (Interleukin-1 receptor-associated kinase 3, also known as IRAK-M) is a 68-70 kDa member of the Pelle subfamily within the TKL Ser/Thr protein kinase family. It functions predominantly as a negative regulator of TLR signaling pathways, with expression primarily limited to macrophages, eosinophils, and respiratory epithelium, including type II alveolar cells . Following TLR activation, IRAK3 forms a complex with MyD88, IRAK1, and IRAK4 on the TLR cytoplasmic domain, which effectively prevents IRAK1/4 phosphorylation and inhibits downstream NF-κB and MAPK activation . This inhibitory function is critical for modulating inflammation in innate immunity and has been associated with various inflammatory conditions, particularly sepsis . Structurally, human IRAK3 spans 596 amino acids, containing one death domain (aa 41-106) and a non-functional protein kinase domain (aa 171-443) .

How do IRAK3 antibodies differ in their detection capabilities across experimental systems?

IRAK3 antibodies vary significantly in their detection capabilities across different experimental platforms and biological samples. For Western blot applications, antibodies such as the Sheep Anti-Human IRAK3 Antigen Affinity-purified Polyclonal Antibody (e.g., AF6264) have demonstrated effectiveness at concentrations of 1 μg/mL when detecting IRAK3 in human cell lines like EOL-1 (acute myeloid leukemia) and THP-1 (acute monocytic leukemia) . These antibodies typically detect IRAK3 at approximately 68 kDa under reducing conditions.

For Simple Western analyses, a higher concentration (20 μg/mL) of the same antibody has been shown to detect IRAK3 at approximately 65 kDa in THP-1 cell lysates loaded at 0.2 mg/mL . This variation in apparent molecular weight (68 kDa vs. 65 kDa) between traditional Western blot and Simple Western platforms highlights the importance of system-specific optimization.

Importantly, researchers must consider species-specific differences when selecting IRAK3 antibodies, as systematic reviews have identified significant variations in IRAK3 expression patterns between humans and rodents, which can affect the translatability of research findings .

In which experimental contexts is IRAK3 expression most reliably detected?

IRAK3 expression is most reliably detected in cell types where it is naturally abundant, particularly in macrophages, eosinophils, and respiratory epithelial cells. Research evidence indicates that baseline and inducible IRAK3 expression patterns show temporal variation between human and rodent models following immune challenges .

In human and mouse cell culture models, IRAK3 mRNA expression significantly increases at intermediate (4h-15h) and long-term (16h-48h) timepoints following immune challenge, though the peak expression timing differs between species . Specifically, human cells typically show peak IRAK3 mRNA levels during intermediate timeframes, while rodent models exhibit maximum expression at later timepoints .

For consistent detection in experimental models, THP-1 human acute monocytic leukemia and EOL-1 human acute myeloid leukemia cell lines have proven to be reliable systems for IRAK3 protein detection using Western blot techniques . When studying the temporal dynamics of IRAK3 expression, researchers should design sampling timepoints that encompass the full range from short-term (5min-3h) through intermediate (4h-15h) to long-term (16h-48h) post-challenge to capture the complete expression profile .

How does IRAK3 antibody detection contribute to understanding sepsis pathophysiology?

IRAK3 antibody detection has become instrumental in elucidating the biphasic nature of sepsis, characterized by an initial hyperinflammatory phase followed by immunosuppression. Meta-analyses of in vivo studies have confirmed IRAK3's inhibitory effect on TNF-α mRNA and protein expression specifically after two immune challenges, demonstrating its association with the immunosuppression phase of sepsis .

Systematic reviews indicate that IRAK3 significantly decreases NF-κB DNA binding activity in cell lines and reduces TNF-α protein levels at intermediate time intervals (4h-15h) in cell lines or at long-term intervals (16h-48h) in mouse primary cells following a single immune challenge . These temporal patterns are critical for understanding IRAK3's role in modulating inflammatory responses during sepsis progression.

The experimental approach for studying IRAK3 in sepsis typically involves:

• One-challenge models: Cells or animals are subjected to treatment with a microbial component or inflammation-modulating chemical, with outcomes measured at specific timepoints afterward

• Two-challenge models: Following initial exposure, subjects receive a second challenge with the same or different stimulant, mimicking the immunosuppression phase of sepsis

Researchers employing IRAK3 antibodies in sepsis studies should be aware of species differences, as patterns of IRAK3 mRNA and protein expression differ significantly between humans and rodents following immune challenge, potentially affecting the translatability of findings from animal models to human disease .

What role does IRAK3 play in cancer progression and how can antibody detection inform therapeutic strategies?

This dual nature makes IRAK3 antibody detection particularly valuable in cancer research for:

• Prognostic assessment: Evaluating IRAK3 protein levels in tumor tissues may help stratify patients according to likely disease outcomes

• Therapeutic planning: IRAK3 expression levels may predict response to various treatment modalities, including immunotherapy, chemotherapy, and molecular targeted therapies

• Understanding tumor immune microenvironment: IRAK3's effects on immune cell function influence cancer immune evasion strategies

Research in LUAD has demonstrated that IRAK3 levels could potentially guide treatment selection, as elevated IRAK3 may predict immunotherapy resistance while simultaneously indicating increased sensitivity to chemotherapeutic and molecular targeted drugs . This highlights the potential value of IRAK3 as a biomarker for personalized cancer treatment approaches.

Researchers employing IRAK3 antibodies in cancer studies should consider the tumor type-specific effects of this protein, as its roles appear to vary significantly across different cancer contexts.

How can IRAK3 antibodies help distinguish its effects from other IRAK family members?

Distinguishing IRAK3's functions from those of other IRAK family members (IRAK1, IRAK2, and IRAK4) presents a significant challenge due to their structural similarities and overlapping roles in immune signaling. Antibody-based approaches can help resolve these distinctions in several ways:

• Specificity validation: Western blot analysis using recombinant human IRAK1, IRAK2, IRAK3, and IRAK4 proteins (loaded at 2 ng/lane) can verify antibody specificity, as demonstrated with the AF6264 antibody that selectively detects IRAK3 without cross-reactivity with other IRAK family members .

• Functional differentiation: Unlike other IRAKs, IRAK3 contains a non-functional protein kinase domain (aa 171-443), making it enzymatically distinct . Antibodies targeting this region can help distinguish IRAK3 from its catalytically active family members.

• Expression pattern analysis: IRAK3 has a more restricted expression profile (primarily in macrophages, eosinophils, and respiratory epithelium) compared to other IRAK family members, which can be leveraged in co-expression studies using cell-type specific markers alongside IRAK3 antibodies .

Researchers should note that IRAK3's effects can be contradictory depending on the experimental model. While generally considered an inhibitor of TLR signaling, IRAK3 has been reported to increase NF-κB activity after LPS challenge in some cell types and can induce NF-κB activity in response to IL-1β stimulation . These context-dependent effects highlight the importance of careful experimental design when using antibodies to study IRAK3 function.

What are the optimal conditions for IRAK3 antibody application in Western blot analyses?

Optimizing IRAK3 antibody applications in Western blot analyses requires careful consideration of several technical parameters. Based on validated protocols, the following conditions have proven effective:

• Antibody concentration: For Sheep Anti-Human IRAK3 Antigen Affinity-purified Polyclonal Antibody (AF6264), a concentration of 1 μg/mL has been effective for standard Western blot applications . This should be paired with appropriate HRP-conjugated secondary antibodies, such as Anti-Sheep IgG Secondary Antibody (e.g., HAF016).

• Sample preparation: For cell lines such as EOL-1 and THP-1, standard lysate preparation under reducing conditions coupled with PVDF membrane transfer has shown reliable results . When analyzing recombinant proteins, loading approximately 2 ng/lane provides sufficient signal without overwhelming the system.

• Buffer systems: Using standardized buffer systems (e.g., Immunoblot Buffer Group 1) helps ensure reproducible results across experiments .

• Molecular weight verification: Researchers should look for IRAK3 detection at approximately 68 kDa in standard Western blot applications, though this may vary slightly (e.g., 65 kDa in Simple Western systems) depending on the specific analytical platform used .

• Validation controls: Including both positive controls (e.g., THP-1 cell lysates known to express IRAK3) and negative controls is essential for confirming antibody specificity.

It's important to note that optimal dilutions may vary by laboratory and application, making preliminary titration experiments advisable when first implementing IRAK3 antibody detection protocols .

How should researchers design experiments to capture IRAK3's temporal effects on inflammatory signaling?

Designing experiments to effectively capture IRAK3's temporal effects on inflammatory signaling requires careful consideration of timepoints, challenge protocols, and readout systems. Based on systematic reviews of IRAK3 research, the following experimental design principles are recommended:

• Timepoint selection: Implement a comprehensive timepoint strategy spanning:

  • Short-term (ST): 5 minutes to 3 hours post-challenge

  • Intermediate-term (IT): 4 to 15 hours post-challenge

  • Long-term (LT): 16 to 48 hours post-challenge

• Challenge protocols: Consider both single-challenge and two-challenge approaches:

  • Single-challenge: Treatment with a microbe or inflammation-modulating chemical with measurements at defined intervals

  • Two-challenge: Initial treatment followed by a second challenge after a defined period, mimicking endotoxin tolerance or sepsis progression

• Readout selection: Measure multiple parameters at each timepoint:

  • IRAK3 expression: Both mRNA and protein levels

  • Inflammatory cytokines: TNF-α and IL-6 at protein and mRNA levels

  • NF-κB activity: With specific timeframes for assessment:

    • Short-term NF-κB (5-30 minutes)

    • Intermediate-term NF-κB (31 minutes-5 hours)

    • Long-term NF-κB (6-24 hours)

• Experimental models: Consider model-specific response patterns:

  • Human cell lines (e.g., THP-1)

  • Mouse primary cells

  • Human primary cells

This comprehensive approach accounts for the complex temporal dynamics of IRAK3 function, including its distinct patterns of expression and activity in different experimental systems. Researchers should be particularly attentive to species-specific differences, as meta-analyses have revealed significant variations in IRAK3 mRNA and protein expression kinetics between humans and rodents following immune challenge .

What control samples are essential when studying IRAK3 in cancer tissues?

When investigating IRAK3 in cancer tissues using antibody-based detection methods, inclusion of appropriate controls is critical for result interpretation and validation. Based on current research practices, the following controls should be considered:

• Adjacent normal tissue: Paired normal tissue from the same patient provides the most relevant baseline for comparing IRAK3 expression levels in cancer samples, accounting for individual variation. This is particularly important in lung adenocarcinoma studies, where IRAK3 levels have prognostic significance .

• Cell line controls:

  • Positive controls: THP-1 human acute monocytic leukemia cells and EOL-1 human acute myeloid leukemia cells reliably express IRAK3 and serve as technical validation controls for antibody performance .

  • Negative controls: Cell lines with minimal IRAK3 expression or IRAK3-knockout cell models provide specificity controls.

• Recombinant protein standards: Purified recombinant human IRAK3 protein at known concentrations (e.g., 2 ng/lane) allows for semi-quantitative assessment and serves as a positive control for antibody specificity .

• Comparative IRAK family controls: Including recombinant IRAK1, IRAK2, and IRAK4 proteins helps confirm antibody specificity for IRAK3 over other family members .

• Functional outcome controls: When associating IRAK3 levels with functional outcomes (e.g., cytotoxic T cell dysfunction), appropriate markers of these processes should be concurrently measured to establish correlative relationships .

Researchers should note that IRAK3 exhibits controversial roles across different cancer types, making context-specific validation particularly important when studying its function in novel cancer models or clinical samples .

How should researchers interpret contradictory findings regarding IRAK3's role in immune modulation?

IRAK3's role in immune modulation has yielded seemingly contradictory findings across different experimental systems and disease contexts. When interpreting such results, researchers should consider:

• Context-dependent activity: While generally characterized as a negative regulator of TLR signaling, IRAK3 exhibits context-specific effects. In certain cellular environments, IRAK3 overexpression can increase NF-κB activity after LPS challenge and induce NF-κB activity in response to IL-1β stimulation . In dendritic cells challenged with IL-33, IRAK3 activates expression of inflammatory cytokines including IL-6, IL-5, and IL-13 .

• Cell type specificity: IRAK3's effects vary significantly between cell types:

  • In macrophages, IRAK3 knockout typically results in increased levels of inflammatory cytokines (IL-6 and TNF-α)

  • In mouse bone marrow-derived dendritic cells, some studies found IRAK3 has no inhibitory role on TNF-α production

  • In other contexts, IRAK3 overexpression requires IRAK1 knockdown to suppress NF-κB activation and TNF-α production

• Temporal dynamics: IRAK3's effects change over time following immune challenge, with meta-analyses showing:

  • Different patterns of TNF-α protein expression in human cell lines versus mouse primary cells

  • Negative correlation between IRAK3 and inflammatory cytokines (IL-6 and TNF-α) specifically after two challenges, but not necessarily after a single challenge

• Species differences: Patterns of IRAK3 mRNA and protein expression differ significantly between humans and rodents, with peak IRAK3 mRNA levels occurring at intermediate timeframes in humans but at later timepoints in rodent models .

When designing studies and interpreting results, researchers should clearly define the specific cellular context, temporal window, and challenge protocol being used, as these factors significantly influence IRAK3's functional outcomes.

What are the limitations of current IRAK3 antibodies in translational research?

Current IRAK3 antibody applications in translational research face several significant limitations that researchers should consider when designing studies and interpreting results:

• Species-specific variability: Systematic reviews have identified substantial differences in IRAK3 expression patterns between humans and rodent models . This variability affects antibody selection for cross-species studies and complicates the translation of findings from animal models to human disease contexts.

• Isoform detection challenges: Human IRAK3 has reported splice variants, including one with a deletion of amino acids 45-105 . Antibodies may have differential reactivity with these variants, potentially missing relevant IRAK3 expression in certain contexts if the epitope falls within variant regions.

• Post-translational modification sensitivity: Human IRAK3 contains six serine phosphorylation sites . Antibodies may have differential reactivity depending on the phosphorylation status, leading to potential under-detection of modified IRAK3 in certain signaling states.

• Context-dependent expression levels: IRAK3's limited expression profile (primarily in macrophages, eosinophils, and respiratory epithelium) means that detection sensitivity becomes critical in tissues with naturally lower IRAK3 levels . Standard antibody concentrations validated in high-expression systems may be insufficient for reliable detection in other contexts.

• Temporal dynamics limitations: Studies show that IRAK3 expression follows complex temporal patterns after immune challenge . Single-timepoint analyses using antibody detection may miss critical expression windows, potentially leading to false-negative results or misinterpretation of IRAK3's role.

To address these limitations, researchers should: (1) validate antibodies in their specific model systems; (2) consider multiple detection methods beyond antibody-based approaches; (3) implement comprehensive timepoint sampling strategies; and (4) carefully contextualize findings within the specific experimental system being used.

How can IRAK3 antibody-based findings inform therapeutic development strategies?

IRAK3 antibody-based research findings provide valuable insights for therapeutic development across several disease contexts:

• Cancer immunotherapy resistance: Research in lung adenocarcinoma has revealed that elevated IRAK3 levels correlate with cytotoxic T lymphocyte dysfunction and predict resistance to immunotherapy through multiple inflammation-related pathways . This suggests that:

  • IRAK3 detection could serve as a biomarker for patient stratification in immunotherapy trials

  • Therapeutic approaches targeting IRAK3 or its downstream effectors might enhance immunotherapy efficacy in patients with elevated IRAK3 expression

  • Combination therapies that modulate IRAK3 activity alongside checkpoint inhibitors warrant investigation

• Sepsis intervention windows: Meta-analyses confirm IRAK3's inhibitory role on inflammatory cytokine expression specifically after two immune challenges, corresponding to the immunosuppression phase of sepsis . This temporal specificity suggests:

  • IRAK3-targeted interventions may require precise timing relative to sepsis progression

  • Therapeutic approaches might differ fundamentally between early (hyperinflammatory) and late (immunosuppressive) sepsis phases

  • Monitoring IRAK3 levels could potentially guide the transition between pro- and anti-inflammatory therapeutic strategies

• Targeted therapy selection: In lung adenocarcinoma, elevated IRAK3 not only predicts immunotherapy resistance but also correlates with increased sensitivity to chemotherapeutic and molecular targeted drugs . This dual predictive capacity suggests that:

  • IRAK3 detection could inform treatment sequence decisions (e.g., chemotherapy before immunotherapy in IRAK3-high patients)

  • Combinatorial approaches targeting both IRAK3 and cancer-specific pathways may yield synergistic benefits

  • Therapeutic development should consider IRAK3's apparent tumor-type specific effects

Researchers developing IRAK3-targeted therapies should note that this protein exhibits context-dependent functions that vary by cell type, disease state, and temporal window . This complexity necessitates careful therapeutic design with consideration of potential on-target effects across multiple physiological systems.

Comparative Analysis of IRAK3 Detection Methods and Applications

Temporal Dynamics of IRAK3 and Inflammatory Markers After Immune Challenge

Data compiled from systematic reviews of IRAK3 expression and function .

Experimental Design Considerations for IRAK3 Research

Table based on methodological considerations from IRAK3 research literature .